Treatment shows promise as adjunctive calciphylaxis therapy

02/14/2013 | Healio

Thrombolytic tissue plasminogen activator was associated with a 30% increase in the survival rate for patients with calciphylaxis, according to a study in the journal JAMA Dermatology. Complications included major and minor bleeding, and six out of 15 patients had blood transfusions.

View Full Article in:

Healio

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC